Cryptosporidiosis Drug Discovery: Opportunities and Challenges
- PMID: 27626293
- DOI: 10.1021/acsinfecdis.6b00094
Cryptosporidiosis Drug Discovery: Opportunities and Challenges
Abstract
The apicomplexan parasite Cryptosporidium is the second most important diarrheal pathogen causing life-threatening diarrhea in children, which is also associated with long-term growth faltering and cognitive deficiency. Cryptosporidiosis is a parasitic disease of public health concern caused by Cryptosporidium parvum and Cryptosporidium hominis. Currently, nitazoxanide is the only approved treatment for cryptosporidium infections. Unfortunately, it has limited efficacy in the most vulnerable patients, thus there is an urgent need for a safe and efficacious cryptosporidiosis drug. In this work, we present our current perspectives on the target product profile for novel cryptosporidiosis therapies and the perceived challenges and possible mitigation plans at different stages in the cryptosporidiosis drug discovery process.
Keywords: Cryptosporidium; cryptosporidiosis; diarrhea; drug discovery; target product profile.
Similar articles
-
Cryptic parasite revealed improved prospects for treatment and control of human cryptosporidiosis through advanced technologies.Adv Parasitol. 2011;77:141-73. doi: 10.1016/B978-0-12-391429-3.00007-1. Adv Parasitol. 2011. PMID: 22137584 Review.
-
Phenotypic screening techniques for Cryptosporidium drug discovery.Expert Opin Drug Discov. 2021 Jan;16(1):59-74. doi: 10.1080/17460441.2020.1812577. Epub 2020 Sep 7. Expert Opin Drug Discov. 2021. PMID: 32892652 Review.
-
A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.PLoS Negl Trop Dis. 2017 Feb 3;11(2):e0005373. doi: 10.1371/journal.pntd.0005373. eCollection 2017 Feb. PLoS Negl Trop Dis. 2017. PMID: 28158186 Free PMC article.
-
Advances in therapeutic and vaccine targets for Cryptosporidium: Challenges and possible mitigation strategies.Acta Trop. 2022 Feb;226:106273. doi: 10.1016/j.actatropica.2021.106273. Epub 2021 Dec 11. Acta Trop. 2022. PMID: 34906550 Review.
-
Recent advances in genetic manipulation of Cryptosporidium.Curr Opin Microbiol. 2020 Dec;58:146-152. doi: 10.1016/j.mib.2020.09.010. Epub 2020 Nov 5. Curr Opin Microbiol. 2020. PMID: 33161368 Free PMC article. Review.
Cited by
-
Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection.J Infect Dis. 2017 Jul 1;216(1):55-63. doi: 10.1093/infdis/jix247. J Infect Dis. 2017. PMID: 28541457 Free PMC article.
-
S-Methylcysteine (SMC) Ameliorates Intestinal, Hepatic, and Splenic Damage Induced by Cryptosporidium parvum Infection Via Targeting Inflammatory Modulators and Oxidative Stress in Swiss Albino Mice.Biomedicines. 2020 Oct 15;8(10):423. doi: 10.3390/biomedicines8100423. Biomedicines. 2020. PMID: 33076496 Free PMC article.
-
Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis.Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7015-7020. doi: 10.1073/pnas.1814685116. Epub 2019 Mar 20. Proc Natl Acad Sci U S A. 2019. PMID: 30894487 Free PMC article.
-
Actives from MMV Open Access Boxes? A suggested way forward.PLoS Pathog. 2021 Apr 22;17(4):e1009384. doi: 10.1371/journal.ppat.1009384. eCollection 2021 Apr. PLoS Pathog. 2021. PMID: 33886696 Free PMC article. Review.
-
The Clofazimine for Treatment of Cryptosporidiosis in HIV-Infected Adults (CRYPTOFAZ) and Lessons Learned for Anticryptosporidial Drug Development.Clin Infect Dis. 2021 Jul 15;73(2):192-194. doi: 10.1093/cid/ciaa425. Clin Infect Dis. 2021. PMID: 32277815 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical